(A) Agilent Technologies - Overview
Stock: Chromatography, Spectrometry, Software, Services, Consumables
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.79% |
| Yield on Cost 5y | 0.84% |
| Yield CAGR 5y | -1.05% |
| Payout Consistency | 66.7% |
| Payout Ratio | 17.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.3% |
| Relative Tail Risk | -7.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -28.29 |
| Character TTM | |
|---|---|
| Beta | 1.079 |
| Beta Downside | 1.029 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.31% |
| CAGR/Max DD | -0.13 |
Description: A Agilent Technologies January 28, 2026
Agilent Technologies (NYSE:A) delivers application-focused solutions across life sciences, diagnostics, and applied chemical markets, organized into three operating segments: Life Sciences & Diagnostics, Agilent CrossLab, and Applied Markets.
The Life Sciences & Diagnostics segment supplies liquid chromatography (LC) and LC-mass spectrometry (LC-MS) systems, and expands into genomics, contract development & manufacturing, pathology, companion diagnostics, and biomolecular analysis. In FY 2023 the segment generated roughly $4.2 billion in revenue, representing about 65 % of total sales.
Agilent CrossLab offers a portfolio of services (repairs, maintenance, compliance support, SaaS, consulting) and consumables (GC/LC columns, sample-prep kits, custom chemistries). It also provides the OpenLab software platform and automated liquid-handling solutions. Q3 2024 showed a 4.5 % year-over-year increase in CrossLab services revenue, driven by higher demand for instrument uptime in pharma R&D.
The Applied Markets segment sells gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments through direct and indirect channels. This segment contributed $1.1 billion in FY 2023, with a modest 2 % growth rate as industrial customers adopt more advanced analytical tools.
Key economic and sector drivers include: (1) a 7 % annual rise in global pharmaceutical R&D spending, boosting demand for high-throughput LC-MS platforms; (2) accelerating adoption of personalized medicine, which fuels growth in companion-diagnostic and biomolecular analysis services; and (3) ongoing supply-chain tightening for high-purity solvents and columns, pressuring margins but also creating pricing power for established suppliers like Agilent.
For a deeper quantitative view, you might explore Agilent’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.30b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.54 > 1.0 |
| NWC/Revenue: 32.34% < 20% (prev 31.71%; Δ 0.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.56b > Net Income 1.30b |
| Net Debt (1.56b) to EBITDA (1.83b): 0.85 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.0m) vs 12m ago -2.41% < -2% |
| Gross Margin: 52.43% > 18% (prev 0.54%; Δ 5189 % > 0.5%) |
| Asset Turnover: 56.55% > 50% (prev 54.96%; Δ 1.59% > 0%) |
| Interest Coverage Ratio: 13.81 > 6 (EBITDA TTM 1.83b / Interest Expense TTM 112.0m) |
Altman Z'' 2.56
| A: 0.18 (Total Current Assets 4.59b - Total Current Liabilities 2.35b) / Total Assets 12.73b |
| B: 0.11 (Retained Earnings 1.39b / Total Assets 12.73b) |
| C: 0.13 (EBIT TTM 1.55b / Avg Total Assets 12.29b) |
| D: 0.19 (Book Value of Equity 1.17b / Total Liabilities 5.99b) |
| Altman-Z'' Score: 2.56 = A |
Beneish M -2.95
| DSRI: 1.05 (Receivables 1.49b/1.32b, Revenue 6.95b/6.51b) |
| GMI: 1.04 (GM 52.43% / 54.30%) |
| AQI: 0.96 (AQ_t 0.48 / AQ_t-1 0.50) |
| SGI: 1.07 (Revenue 6.95b / 6.51b) |
| TATA: -0.02 (NI 1.30b - CFO 1.56b) / TA 12.73b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of A shares?
Over the past week, the price has changed by -3.19%, over one month by -12.21%, over three months by -11.99% and over the past year by -11.53%.
Is A a buy, sell or hold?
- StrongBuy: 9
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 169.7 | 30.9% |
| Analysts Target Price | 169.7 | 30.9% |
| ValueRay Target Price | 128.1 | -1.2% |
A Fundamental Data Overview February 04, 2026
P/E Forward = 22.3714
P/S = 5.5243
P/B = 5.6292
P/EG = 1.8051
Revenue TTM = 6.95b USD
EBIT TTM = 1.55b USD
EBITDA TTM = 1.83b USD
Long Term Debt = 3.05b USD (from longTermDebt, last quarter)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.56b USD (from netDebt column, last quarter)
Enterprise Value = 39.95b USD (38.38b + Debt 3.35b - CCE 1.79b)
Interest Coverage Ratio = 13.81 (Ebit TTM 1.55b / Interest Expense TTM 112.0m)
EV/FCF = 34.68x (Enterprise Value 39.95b / FCF TTM 1.15b)
FCF Yield = 2.88% (FCF TTM 1.15b / Enterprise Value 39.95b)
FCF Margin = 16.58% (FCF TTM 1.15b / Revenue TTM 6.95b)
Net Margin = 18.75% (Net Income TTM 1.30b / Revenue TTM 6.95b)
Gross Margin = 52.43% ((Revenue TTM 6.95b - Cost of Revenue TTM 3.31b) / Revenue TTM)
Gross Margin QoQ = 51.80% (prev 52.59%)
Tobins Q-Ratio = 3.14 (Enterprise Value 39.95b / Total Assets 12.73b)
Interest Expense / Debt = 0.81% (Interest Expense 27.0m / Debt 3.35b)
Taxrate = 1.81% (8.00m / 442.0m)
NOPAT = 1.52b (EBIT 1.55b * (1 - 1.81%))
Current Ratio = 1.96 (Total Current Assets 4.59b / Total Current Liabilities 2.35b)
Debt / Equity = 0.50 (Debt 3.35b / totalStockholderEquity, last quarter 6.74b)
Debt / EBITDA = 0.85 (Net Debt 1.56b / EBITDA 1.83b)
Debt / FCF = 1.36 (Net Debt 1.56b / FCF TTM 1.15b)
Total Stockholder Equity = 6.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.61% (Net Income 1.30b / Total Assets 12.73b)
RoE = 20.62% (Net Income TTM 1.30b / Total Stockholder Equity 6.32b)
RoCE = 16.51% (EBIT 1.55b / Capital Employed (Equity 6.32b + L.T.Debt 3.05b))
RoIC = 15.62% (NOPAT 1.52b / Invested Capital 9.72b)
WACC = 9.16% (E(38.38b)/V(41.74b) * Re(9.89%) + D(3.35b)/V(41.74b) * Rd(0.81%) * (1-Tc(0.02)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 73.53% ; FCFF base≈1.24b ; Y1≈1.21b ; Y5≈1.22b
Fair Price DCF = 56.45 (EV 17.57b - Net Debt 1.56b = Equity 16.00b / Shares 283.5m; r=9.16% [WACC]; 5y FCF grow -3.53% → 2.90% )
EPS Correlation: 44.14 | EPS CAGR: 7.55% | SUE: 0.47 | # QB: 0
Revenue Correlation: 8.56 | Revenue CAGR: 2.86% | SUE: 1.10 | # QB: 3
EPS next Quarter (2026-04-30): EPS=1.39 | Chg30d=+0.001 | Revisions Net=+1 | Analysts=16
EPS current Year (2026-10-31): EPS=5.93 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+6.2% | Growth Revenue=+5.9%
EPS next Year (2027-10-31): EPS=6.55 | Chg30d=-0.015 | Revisions Net=-3 | Growth EPS=+10.3% | Growth Revenue=+6.2%